Organon & Co. reported $6.13B of revenue over the trailing twelve months, −2.5% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $6.13B (to Q2 2026). Net Income: $209M, trailing twelve months to Q2 2026. Free Cash Flow: $567M, trailing twelve months to Q2 2026. EPS: $0.78, trailing twelve months to Q2 2026.

OGNOrganon & Co.

HealthcareUSD

$13.77

$5.6952 weeks$13.77

OGN as reported

Organon & Co. reported $6.13B of revenue over the trailing twelve months, −2.5% on the year before. 9 reported series are charted on this page, each one as filed.

$6.13B

Revenue, trailing twelve months · to Q2 2026 · −2.5% against the twelve months before

Net Income: $209M
Net Income · −70% year on year · trailing twelve months to Q2 2026
Free Cash Flow: $567M
Free Cash Flow · −14% year on year · trailing twelve months to Q2 2026
EPS: $0.78
EPS · −71% year on year · trailing twelve months to Q2 2026

Every series Ryufin has for OGN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$6.13B	−2.5%	Q2 2026
Net Income	$209M	−70%	Q2 2026
EPS	$0.78	−71%	Q2 2026
Gross Margin	53%	n/a	Q2 2026
Net Margin	3.3%	n/a	Q2 2026
ROE	32%	n/a	Q2 2026
ROA	2.2%	n/a	Q2 2026
Free Cash Flow	$567M	−14%	Q2 2026
P/E	17.6	n/a	today